Johnson & Johnson’s Varipulse Platform shows effectiveness, safety in study

Johnson & Johnson’s Johnson & Johnson MedTech, which deals in cardiac arrhythmia treatment, announced acute safety and effectiveness results from the VARIPURE substudy of SECURE, evaluating the Varipulse Platform in pulsed field ablation, or PFA, procedures for atrial fibrillation, or AF. The real-world data, presented at the 2025 European Society of Cardiology Congress in Madrid, demonstrated a strong safety profile, high acute effectiveness and procedural efficiency within the 791 patients included in this analysis: notably, a 0.6% primary adverse rate with no strokes was reported along with 99.7% acute PVI and high adherence to the recommended ablation workflow. Varipulse, a SECURE substudy, is a prospective, observational, post-market study conducted across 20 European centers, including 62 operators, that evaluated acute safety, effectiveness, and procedural characteristics of index AF ablations performed with the Varipulse Platform. The Varipulse Platform consists of the Varipulse Catheter and Trupulse Generator, which integrates with the Carto 3 System for AF.